OBJECTIVE: To examine in vivo levels of beta-amyloid (Abeta) oligomers (oAbeta) vs monomeric Abeta in plasma and brain tissue of patients with sporadic and familial Alzheimer disease (AD) using a new enzyme-linked immunosorbent assay (ELISA) specific for oAbeta. DESIGN: To establish the oAbeta ELISA, the same N-terminal Abeta antibody was used for antigen capture and detection. Plasma and postmortem brain tissue from patients with AD and control subjects were systematically analyzed by conventional monomeric Abeta and new oAbeta ELISAs. SUBJECTS: We measured oAbeta species in plasma samples from 36 patients with clinically well-characterized AD and 10 control subjects. In addition, postmortem samples were obtained from brain autopsies of 9 patients with verified AD and 7 control subjects. MAIN OUTCOME MEASURES: Oligomeric Abeta and 4 monomeric Abeta species in plasma samples from patients with AD and control subjects were measured by ELISA. RESULTS: The specificity of the oAbeta ELISA was validated with a disulfide-crossed-linked, synthetic Abeta(1-40)Ser26Cys dimer that was specifically detected before but not after the dissociation of the dimers in beta-mercaptoethanol. Plasma assays showed that relative oAbeta levels were closely associated with relative Abeta(42) monomer levels across all of the subjects. Analysis of sequential plasma samples from a subset of the patients with AD, including a patient with AD caused by a presenilin mutation, revealed decreases in both oAbeta and Abeta(42) monomer levels over a 1- to 2-year period. In brain tissue from 9 patients with AD and 7 control subjects, both oAbeta and monomeric Abeta(42) levels were consistently higher in the AD cases. CONCLUSIONS: An oAbeta-specific ELISA reveals a tight link between oAbeta and Abeta(42) monomer levels in plasma and brain. Both forms can decline over time in plasma, presumably reflecting their increasing insolubility in the brain.
OBJECTIVE: To examine in vivo levels of beta-amyloid (Abeta) oligomers (oAbeta) vs monomeric Abeta in plasma and brain tissue of patients with sporadic and familial Alzheimer disease (AD) using a new enzyme-linked immunosorbent assay (ELISA) specific for oAbeta. DESIGN: To establish the oAbeta ELISA, the same N-terminal Abeta antibody was used for antigen capture and detection. Plasma and postmortem brain tissue from patients with AD and control subjects were systematically analyzed by conventional monomeric Abeta and new oAbeta ELISAs. SUBJECTS: We measured oAbeta species in plasma samples from 36 patients with clinically well-characterized AD and 10 control subjects. In addition, postmortem samples were obtained from brain autopsies of 9 patients with verified AD and 7 control subjects. MAIN OUTCOME MEASURES: Oligomeric Abeta and 4 monomeric Abeta species in plasma samples from patients with AD and control subjects were measured by ELISA. RESULTS: The specificity of the oAbeta ELISA was validated with a disulfide-crossed-linked, synthetic Abeta(1-40)Ser26Cys dimer that was specifically detected before but not after the dissociation of the dimers in beta-mercaptoethanol. Plasma assays showed that relative oAbeta levels were closely associated with relative Abeta(42) monomer levels across all of the subjects. Analysis of sequential plasma samples from a subset of the patients with AD, including a patient with AD caused by a presenilin mutation, revealed decreases in both oAbeta and Abeta(42) monomer levels over a 1- to 2-year period. In brain tissue from 9 patients with AD and 7 control subjects, both oAbeta and monomeric Abeta(42) levels were consistently higher in the AD cases. CONCLUSIONS: An oAbeta-specific ELISA reveals a tight link between oAbeta and Abeta(42) monomer levels in plasma and brain. Both forms can decline over time in plasma, presumably reflecting their increasing insolubility in the brain.
Authors: N Ertekin-Taner; N Graff-Radford; L H Younkin; C Eckman; M Baker; J Adamson; J Ronald; J Blangero; M Hutton; S G Younkin Journal: Science Date: 2000-12-22 Impact factor: 47.728
Authors: Ganesh M Shankar; Shaomin Li; Tapan H Mehta; Amaya Garcia-Munoz; Nina E Shepardson; Imelda Smith; Francesca M Brett; Michael A Farrell; Michael J Rowan; Cynthia A Lemere; Ciaran M Regan; Dominic M Walsh; Bernardo L Sabatini; Dennis J Selkoe Journal: Nat Med Date: 2008-06-22 Impact factor: 53.440
Authors: N Ertekin-Taner; L H Younkin; D M Yager; F Parfitt; M C Baker; S Asthana; M L Hutton; S G Younkin; N R Graff-Radford Journal: Neurology Date: 2007-10-03 Impact factor: 9.910
Authors: Oskar Hansson; Henrik Zetterberg; Eugeen Vanmechelen; Hugo Vanderstichele; Ulf Andreasson; Elisabet Londos; Anders Wallin; Lennart Minthon; Kaj Blennow Journal: Neurobiol Aging Date: 2008-05-19 Impact factor: 4.673
Authors: J M Ringman; S G Younkin; D Pratico; W Seltzer; G M Cole; D H Geschwind; Y Rodriguez-Agudelo; B Schaffer; J Fein; S Sokolow; E R Rosario; K H Gylys; A Varpetian; L D Medina; J L Cummings Journal: Neurology Date: 2008-05-28 Impact factor: 9.910
Authors: Erik Stomrud; Oskar Hansson; Lennart Minthon; Kaj Blennow; Ingmar Rosén; Elisabet Londos Journal: Neurobiol Aging Date: 2010-02 Impact factor: 4.673
Authors: Johan Sundelöf; Vilmantas Giedraitis; Michael C Irizarry; Johan Sundström; Erik Ingelsson; Elina Rönnemaa; Johan Arnlöv; Malin Degerman Gunnarsson; Bradley T Hyman; Hans Basun; Martin Ingelsson; Lars Lannfelt; Lena Kilander Journal: Arch Neurol Date: 2008-02
Authors: Victor L Villemagne; Keyla A Perez; Kerryn E Pike; W Mei Kok; Christopher C Rowe; Anthony R White; Pierrick Bourgeat; Olivier Salvado; Justin Bedo; Craig A Hutton; Noel G Faux; Colin L Masters; Kevin J Barnham Journal: J Neurosci Date: 2010-05-05 Impact factor: 6.167
Authors: Sam Gandy; Adam J Simon; John W Steele; Alex L Lublin; James J Lah; Lary C Walker; Allan I Levey; Grant A Krafft; Efrat Levy; Frédéric Checler; Charles Glabe; Warren B Bilker; Ted Abel; James Schmeidler; Michelle E Ehrlich Journal: Ann Neurol Date: 2010-08 Impact factor: 10.422
Authors: Thomas J Esparza; Hanzhi Zhao; John R Cirrito; Nigel J Cairns; Randall J Bateman; David M Holtzman; David L Brody Journal: Ann Neurol Date: 2012-12-07 Impact factor: 10.422
Authors: Katherine L Youmans; Leon M Tai; Evelyn Nwabuisi-Heath; Lisa Jungbauer; Takahisa Kanekiyo; Ming Gan; Jungsu Kim; William A Eimer; Steve Estus; G William Rebeck; Edwin J Weeber; Guojun Bu; Chunjiang Yu; Mary Jo Ladu Journal: J Biol Chem Date: 2012-10-11 Impact factor: 5.157
Authors: André F Martins; Alexandre C Oliveira; Jean-François Morfin; Douglas V Laurents; Éva Tóth; Carlos F G C Geraldes Journal: J Biol Inorg Chem Date: 2015-11-27 Impact factor: 3.358